The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

被引：0
|
作者：
Pawlyn, Charlotte
Menzies, Tom
Davies, Faith E.
Rana, Ritika
Pinney, Jennifer
Cook, Gordon
Gregory, Walter Martin
Jenner, Matthew W.
Jones, John R.
Kaiser, Martin F.
Owen, Roger G.
Morgan, Gareth
Jackson, Graham H.
Cairns, David
Drayson, Mark T.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial
    Pawlyn, C.
    Davies, F.
    Cairns, D.
    Striha, A.
    Best, P.
    Sigsworth, R.
    Jones, J.
    Kishore, B.
    Garg, M.
    Williams, C.
    Karunanithi, K.
    Lindsay, J.
    Jenner, M.
    Cook, G.
    Kaiser, M.
    Drayson, M.
    Owen, R.
    Russell, N.
    Gregory, W.
    Jackson, G.
    Morgan, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 15 - 16
  • [2] Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial
    Pawlyn, Charlotte
    Davies, Faith E.
    Cairns, David
    Striha, Alina
    Best, Phillip
    Sigsworth, Rachel
    Jones, John R.
    Kishore, Bhuvan
    Garg, Mamta
    Williams, Cathy
    Karunanithi, Kamaraj
    Lindsay, Jindriska
    Jenner, Matthew W.
    Cook, Gordon
    Kaiser, Martin F.
    Drayson, Mark T.
    Owen, Roger G.
    Russell, Nigel H.
    Gregory, Walter M.
    Jackson, Graham
    Morgan, Gareth J.
    BLOOD, 2017, 130
  • [3] CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA PATIENTS: SUBGROUP ANALYSIS IN THE FORTE TRIAL
    Gay, F.
    Cerrato, C.
    Petrucci, M. T.
    Zambello, R.
    Rivolti, E.
    Ballanti, S.
    Omede, P.
    Gentile, M.
    Bernardini, A.
    Narni, F.
    Capra, A.
    De Sabbata, G.
    Gozzetti, A.
    Galieni, P.
    Rizzi, R.
    Pescosta, N.
    Cea, M.
    Molica, S.
    Cafro, A.
    Musolino, C.
    Spadano, A.
    Montefusco, V.
    Musto, P.
    Cavo, M.
    Boccadoro, M.
    HAEMATOLOGICA, 2019, 104 : 2 - 3
  • [4] Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
    Jones, John R.
    Cairns, David A.
    Menzies, Tom
    Pawlyn, Charlotte
    Davies, Faith E.
    Sigsworth, Rachel
    Brioli, Annamaria
    Jenner, Matthew W.
    Kaiser, Martin F.
    Olivier, Catherine
    Reed, Molly
    Drayson, Mark T.
    Owen, Roger G.
    Boyd, Kevin D.
    Cook, Gordon
    Morgan, Gareth J.
    ECLINICALMEDICINE, 2023, 62
  • [5] Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
    Shah, Vallari
    Sherborne, Amy L.
    Johnson, David C.
    Ellis, Sidra
    Price, Amy
    Chowdhury, Farzana
    Kendall, Jack
    Jenner, Matthew W.
    Drayson, Mark T.
    Owen, Roger G.
    Gregory, Walter M.
    Morgan, Gareth J.
    Davies, Faith E.
    Cook, Gordon
    Cairns, David A.
    Houlston, Richard S.
    Jackson, Graham
    Kaiser, Martin F.
    LEUKEMIA, 2020, 34 (11) : 3091 - 3096
  • [6] Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
    Vallari Shah
    Amy L. Sherborne
    David C. Johnson
    Sidra Ellis
    Amy Price
    Farzana Chowdhury
    Jack Kendall
    Matthew W. Jenner
    Mark T. Drayson
    Roger G. Owen
    Walter M. Gregory
    Gareth J. Morgan
    Faith E. Davies
    Gordon Cook
    David A. Cairns
    Richard S. Houlston
    Graham Jackson
    Martin F. Kaiser
    Leukemia, 2020, 34 : 3091 - 3096
  • [7] Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma
    Yoshihara, Satoshi
    Yoshihara, Kyoko
    Shimizu, Yoshifumi
    Imado, Takehito
    Takatsuka, Hiroyuki
    Kawamoto, Hiroyuki
    Misawa, Mahito
    Ifuku, Hideki
    Ohe, Yokiko
    Okada, Masaya
    Fujimori, Yoshihiro
    HEMATOLOGY, 2021, 26 (01) : 388 - 392
  • [8] Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI plus ): Interim analysis of an open-label randomised controlled trial
    Jackson, Graham H.
    Pawlyn, Charlotte
    Cairns, David A.
    de Tute, Ruth M.
    Hockaday, Anna
    Collett, Corinne
    Jones, John R.
    Kishore, Bhuvan
    Garg, Mamta
    Williams, Cathy D.
    Karunanithi, Kamaraj
    Lindsay, Jindriska
    Rocci, Alberto
    Snowden, John A.
    Jenner, Matthew W.
    Cook, Gordon
    Russell, Nigel H.
    Drayson, Mark T.
    Gregory, Walter M.
    Kaiser, Martin F.
    Owen, Roger G.
    Davies, Faith E.
    Morgan, Gareth J.
    PLOS MEDICINE, 2021, 18 (01)
  • [9] The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Merz, Maximilian
    Dechow, Tobias
    Scheytt, Mithun
    Schmidt, Christian
    Hackanson, Bjoern
    Knop, Stefan
    ANNALS OF HEMATOLOGY, 2020, 99 (08) : 1709 - 1725
  • [10] The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Maximilian Merz
    Tobias Dechow
    Mithun Scheytt
    Christian Schmidt
    Bjoern Hackanson
    Stefan Knop
    Annals of Hematology, 2020, 99 : 1709 - 1725
12345